Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GX-G6 in healthy volunteers
NCT03651466Phase 1Completed
- Sponsor
- Genexine
- Start
- Aug 2017
- Primary completion
- Jun 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GX-G6 in type 2 diabetes mellitus (T2DM) (6 cohorts), sponsored by Genexine. Primary endpoint: Incidence, nature and severity of Adverse events at 4 weeks. Started Aug 2017; status: completed.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03651466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651466.